Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals

References

• International Diabetes Federation. IDF Diabetes Atlas. 6th edition. Brussels, Belgium: 2013
   Google Scholar
• Ali MK, Bullard KM, Gregg EW, Del Rio C. A cascade of care for diabetes in the United States: visualizing the gaps. Ann Intern Med 2014;161:681–9
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033–46
   PubMed Web of Science ®Google Scholar
• Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773–95
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013;36 Suppl 2:S127–38
   Google Scholar
• Blonde L, San Juan ZT, Bolton P. Fixed-dose combination therapy in type 2 diabetes mellitus. Endocr Pract 2014;20:1322–32
   PubMed Web of Science ®Google Scholar
• Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 2007;27:1102–10
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005–12
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 2015;21:438–47
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the american diabetes association and the european association for the study of diabetes. Diabetes Care 2015;38:140–9
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract 2015;21:1–87
   PubMed Web of Science ®Google Scholar
• Bell DS. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab 2013;15:291–300
   PubMed Web of Science ®Google Scholar
• Bohannon NJ. Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician. Postgrad Med 2012;124:95–108
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Professional practice committee for the standards of medical care in diabetes-2015. Diabetes Care 2015;38:S88–9
   Web of Science ®Google Scholar
• Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther 2001;23:1311–20
   PubMed Web of Science ®Google Scholar
• Dailey G, Kim MS, Lian JF. Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res 2002;30:71–9
   PubMed Web of Science ®Google Scholar
• Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med 2002;19:279–84
   PubMed Web of Science ®Google Scholar
• Østbye T, Yarnall KS, Krause KM, Pollak KI, Gradison M, Michener JL. Is there time for management of patients with chronic diseases in primary care? Ann Fam Med 2005;3:209–14
   PubMed Web of Science ®Google Scholar
• Brummel A, Lustig A, Westrich K, Evans MA, Plank GS, Penso J, Dubois RW. Best practices: improving patient outcomes and costs in an ACO through comprehensive medication therapy management. J Manag Care Spec Pharm 2014;20:1152–8
   Web of Science ®Google Scholar
• Smith M. Pharmacists’ role in improving diabetes medication management. J Diabetes Sci Technol 2009;3:175–9
   PubMedGoogle Scholar
• Haas L, Maryniuk M, Beck J, Cox CE, Duker P, Edwards L, et al. National standards for diabetes self-management education and support. Diabetes Care 2012;35:2393–401
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. (7) Approaches to glycemic treatment. Diabetes Care 2015;38 Suppl:S41–8
   Google Scholar
• Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2014;16:410–17
   PubMed Web of Science ®Google Scholar
• Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B; Global Partnership for Effective Diabetes Management. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract 2005;59:1345–55
   PubMed Web of Science ®Google Scholar
• Bailey T. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. Am J Med 2013;126:S10–20
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Aschner P, Del Prato S, LaSalle J, Ji L, Matthaei S; Global Partnership for Effective Diabetes Management. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. Diab Vasc Dis Res 2013;10:397–409
   PubMed Web of Science ®Google Scholar
• Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the european society of cardiology (ESC) and developed in collaboration with the european association for the study of diabetes (EASD). Eur Heart J 2013;34:3035–87
   PubMed Web of Science ®Google Scholar
• U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995;44:1249–58
   PubMed Web of Science ®Google Scholar
• Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005;28:600–6
   PubMed Web of Science ®Google Scholar
• Ziemer DC, Miller CD, Rhee MK, Doyle JP, Watkins CJr, Cook CB, et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ 2005;31:564–71
   PubMed Web of Science ®Google Scholar
• Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 2013;36:3411–17
   PubMed Web of Science ®Google Scholar
• Garber AJ. Using dose–response characteristics of therapeutic agents for treatment decisions in type 2 diabetes. Diabetes Obes Metab 2000;2:139–47
   PubMed Web of Science ®Google Scholar
• Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ, Strow LJ. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin 2005;21:2029–35
   PubMed Web of Science ®Google Scholar
• Raz I. Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013;36:S139–44
   PubMed Web of Science ®Google Scholar
• Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin 2011;27:1157–68
   PubMed Web of Science ®Google Scholar
• Benford M, Milligan G, Pike J, Anderson P, Piercy J, Fermer S. Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther 2012;29:26–40
   PubMed Web of Science ®Google Scholar
• Han S, Iglay K, Davies MJ, Zhang Q, Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin 2012;28:969–77
   PubMed Web of Science ®Google Scholar
• Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2012;14:565–74
   PubMed Web of Science ®Google Scholar
• Garber AJ, Donovan DSJr, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003;88:3598–604
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Pans M, Rubin CJ. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther 2003;25:890–903
   PubMed Web of Science ®Google Scholar
• JANUMET® (sitagliptin and metformin HCl) tablets. Full prescribing information. Merck & Co, Inc., 2015. Available from http://www.merck.com/product/usa/pi_circulars/j/janumet/janumet_pi.pdf. Last accessed 7 July 2015
   Google Scholar
• JANUMET® XR (sitagliptin and metformin HCl extended-release) tablets. Full prescribing information. Merck & Co, Inc., 2015. Available from http://www.merck.com/product/usa/pi_circulars/j/janumet_xr/janumet_xr_pi.pdf. Last accessed 7 July 2015
   Google Scholar
• JENTADUETO® (linagliptin and metformin hydrochloride) tablets. Full prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc., 2014. Available from http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Jentadueto/Jentadueto.pdf. Last accessed 7 July 2015
   Google Scholar
• Kombiglyze™ XR (saxagliptin and metformin hydrochloride extended-release) tablets, for oral use. Full prescribing information. AstraZeneca Pharmaceuticals LP, 2014. Available from http://www.azpicentral.com/kombiglyze-xr/pi_kombiglyze_xr.pdf#page=1. Last accessed 7 July 2015
   Google Scholar
• KAZANO® (alogliptin benzoate and metformin hydrochloride tablet, film coated). Full rescribing information. Takeda Pharmaceuticals America, Inc., 2013. Available from http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83cb7914-a683-47bb-a713-f2bc6a596bd2. Last accessed 7 July 2015
   Google Scholar
• Glipizide and metformin hydrochloride tablets, film coated. Full prescribing information. Mylan Pharmaceuticals, Inc., 2015. Available from http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2a44879-6ab7-5d62-0f96-2bec51eefc57. Last accessed 7 July 2015
   Google Scholar
• Glyburide and metformin hydrochloride tablet, film coated. Full prescribing information. Teva Pharmaceuticals USA, Inc., 2014. Available from http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12020b5c-f667-4db3-8ae2-8d08c60b48d8. Last accessed 7 July 2015
   Google Scholar
• XIGDUO™ XR (dapagliflozin and metformin HCL extended-release) tablets, for oral use. Full prescribing information. AstraZeneca Pharmaceuticals LP, 2014. Available from http://www.azpicentral.com/xigduo/pi_xigduoxr.pdf#page=1. Last accessed 7 July 2015
   Google Scholar
• INVOKAMET® (canagliflozin and metformin hydrochloride) tablets, for oral use. Full prescribing information. Janssen Pharmaceuticals, Inc., 2015. Available from http://www.invokanahcp.com/invokamet/prescribing-information.pdf. Last accessed 7 July 2015
   Google Scholar
• SYNJARDY® (empagliflozin and metformin hydrochloride) tablets. Full prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc., 2015. Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Synjardy/Synjardy.pdf. Last accessed 11 September 2015
   Google Scholar
• PrandiMet® (repaglinide/metformin HCl) tablets. Full prescribing information. Novo Nordisk, Inc., 2012. Available from http://www.novo-pi.com/prandimet.pdf. Last accessed 17 March 2015
   Google Scholar
• ACTOPLUS MET® (pioglitazone hydrochloride and metformin hydrochloride) tablets, film coated. Full prescribing information. Takeda Pharmaceuticals America, Inc., 2014. Available from http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66. Last accessed 7 July 2015
   Google Scholar
• Actoplus Met® XR (pioglitazone hydrochloride and metformin hydrochloride) tablets, film coated, extended release. Full prescribing information. Takeda Pharmaceuticals America, Inc., 2013. Available from http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f986164c-51a7-41c2-8952-511b8f46d593. Last accessed 7 July 2015
   Google Scholar
• Slabaugh SL, Xu Y, Stacy JN, Baltz JC, Meah YA, Lian J, et al. Antidiabetic treatment patterns in a medicare advantage population in the United States. Drugs Aging 2015;32:169–78
   PubMed Web of Science ®Google Scholar
• Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care 2014;37:1367–74
   PubMed Web of Science ®Google Scholar
• Fu H, Xie W, Curtis B, Schuster D. Identifying factors associated with hypoglycemia-related hospitalizations among elderly patients with T2DM in the US: a novel approach using influential variable analysis. Curr Med Res Opin 2014;30:1787–93
   PubMed Web of Science ®Google Scholar
• Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:938–53
   PubMed Web of Science ®Google Scholar
• Li Y, Hu Y, Ley SH, Rajpathak S, Hu FB. Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. Diabetes Care 2014;37:3106–13
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–89
   PubMed Web of Science ®Google Scholar
• Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007;292:E871–83
   PubMed Web of Science ®Google Scholar
• Liu Y, Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes Obes Metab 2014;16:111–17
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223–33
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941–50
   PubMed Web of Science ®Google Scholar
• Häring H-U, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014;37:1650–9
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood US Food and Drug Administration. Available from http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. Last accessed 13 July 2015
   Google Scholar
• Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687–93
   PubMed Web of Science ®Google Scholar
• Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab 2015;100:2849–52
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2013;124:499–508
   Web of Science ®Google Scholar
• Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124:509–14
   PubMed Web of Science ®Google Scholar
• Hanefeld M. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. Int J Clin Pract Suppl 2007;20–7
   PubMedGoogle Scholar
• Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10–17
   PubMed Web of Science ®Google Scholar
• DUETACT® (pioglitazone hydrochloride and glimepiride) tablet. Full prescribing information. Takeda Pharmaceuticals America, Inc., 2015. Available from http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458. Last accessed 7 July 2015
   Google Scholar
• Henry RR, Staels B, Fonseca VA, Chou MZ, Teng R, Golm GT, et al. Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study. Diabetes Obes Metab 2014;16:223–30
   PubMed Web of Science ®Google Scholar
• Karyekar C, Donovan M, Allen E, Fleming D, Ravichandran S, Chen R. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. Postgrad Med 2011;123:63–70
   PubMed Web of Science ®Google Scholar
• Mikhail N. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. Vasc Health Risk Manag 2008;4:1221–7
   PubMedGoogle Scholar
• Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 009 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009;25:2361–71
   PubMed Web of Science ®Google Scholar
• Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O’Neill EA, et al. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study. Diabetes Obes Metab 2012;14:745–52
   PubMed Web of Science ®Google Scholar
• Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:653–61
   PubMed Web of Science ®Google Scholar
• OSENI® (alogliptin and pioglitazone) tablets. Full prescribing information. Takeda Pharmaceuticals America, Inc., 2013. Available from http://general.takedapharm.com/content/file.aspx?applicationcode=261C8AE7-63CB-4BEA-80B5-C821D5CC17BB&filetypecode=OSENIPI&cacheRandomizer=6555185b-a88c-4550-a9ee-a8752af566e3. Last accessed 7 July 2015
   Google Scholar
• Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015;38:376–83
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015;38:384–93
   PubMed Web of Science ®Google Scholar
• Lewin A, DeFronzo RA, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 2015;38:394–402
   PubMed Web of Science ®Google Scholar
• Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011;13:928–38
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–15
   PubMed Web of Science ®Google Scholar
• Häring H, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013;36:3396–404
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35:1473–8
   PubMed Web of Science ®Google Scholar
• Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, Stein P. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014;16:467–77
   PubMed Web of Science ®Google Scholar
• Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16:147–58
   PubMed Web of Science ®Google Scholar
• GLYXAMBI® (empagliflozin and linagliptin) tablets, for oral use. Full prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc., 2015. Available from http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Glyxambi/Glyxambi.pdf. Last accessed 7 July 2015
   Google Scholar
• Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2013;15:485–502
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Bertolini M, Tinahones FJ, Domingo MP, Davies M. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. J Diabetes Complications 2014;28:880–6
   PubMed Web of Science ®Google Scholar
• Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014;384:2228–34
   PubMed Web of Science ®Google Scholar
• Kumar A. Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy. Expert Opin Biol Ther 2014;14:869–78
   PubMed Web of Science ®Google Scholar
• Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2014;2:885–93
   PubMed Web of Science ®Google Scholar
• Buse JB, Vilsbøll T, Thurman J, Blevins TC, Langbakke IH, Bøttcher SG, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care 2014;37:2926–33
   PubMed Web of Science ®Google Scholar
• Xultophy® (insulin degludec and liraglutide). Summary of Product Characteristics (November 2014). European Medicines Agency, 2014. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002647/WC500177657.pdf. Last accessed 11 February 2015
   Google Scholar
• Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011;33:74–109
   PubMed Web of Science ®Google Scholar
• Salas M, Hughes D, Zuluaga A, Vardeva K, Lebmeier M. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health 2009;12:915–22
   PubMed Web of Science ®Google Scholar
• Quilliam BJ, Simeone JC, Ozbay AB, Kogut SJ. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care 2011;17:673–80
   PubMed Web of Science ®Google Scholar
• Dellasega C, Añel-Tiangco RM, Gabbay RA. How patients with type 2 diabetes mellitus respond to motivational interviewing. Diabetes Res Clin Pract 2012;95:37–41
   PubMed Web of Science ®Google Scholar
• Miller WR, Rose GS. Toward a theory of motivational interviewing. Am Psychol 2009;64:527–37
   PubMed Web of Science ®Google Scholar
• Platt FW, Gaspar DL, Coulehan JL, Fox L, Adler AJ, Weston WW, et al. “Tell me about yourself”: The patient-centered interview. Ann Intern Med 2001;134:1079–85
   PubMed Web of Science ®Google Scholar